Trial Profile
Efficacy of BELImumab for therapy-resistant SKIN manifestations in patients with lupus erythematosus (LE): A phase III, multicenter, randomized, double-blind, placebo-controlled, 24-week trial (BELI-SKIN)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms BELI-SKIN
- 16 Feb 2024 Status changed from recruiting to completed.
- 18 Oct 2018 New trial record